Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08

Background Regorafenib or trifluridine/tipiracil as third-line treatment have limited efficacy in metastatic colorectal cancer (mCRC). Methods This Phase 2 trial evaluated the efficacy and safety of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type mCRC patients who ach...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer Vol. 123; no. 10; pp. 1490 - 1495
Main Authors: Masuishi, Toshiki, Tsuji, Akihito, Kotaka, Masahito, Nakamura, Masato, Kochi, Mitsugu, Takagane, Akinori, Shimada, Ken, Denda, Tadamichi, Segawa, Yoshihiko, Tanioka, Hiroaki, Hara, Hiroki, Sagawa, Tamotsu, Watanabe, Takanori, Takahashi, Takao, Negoro, Yuji, Manaka, Dai, Fujita, Hideto, Suto, Takeshi, Takeuchi, Masahiro, Ichikawa, Wataru, Fujii, Masashi
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 10.11.2020
Nature Publishing Group
Subjects:
ISSN:0007-0920, 1532-1827, 1532-1827
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first